Plavix

Atrial Fibrillation, Angina, Unstable, Heart Attack + 9 more
Treatment
19 FDA approvals
20 Active Studies for Plavix

What is Plavix

ClopidogrelThe Generic name of this drug
Treatment SummaryClopidogrel is a medication used to reduce the risk of heart attack and stroke in people with non-ST elevated acute coronary syndrome, people with ST-elevated myocardial infarction, and people with recent or established peripheral arterial disease. It is more effective than aspirin at reducing cardiovascular outcomes in people with cardiovascular disease and it provides additional benefits for those who are already taking aspirin. Clopidogrel was approved by the FDA in 1997.
Plavixis the brand name
image of different drug pills on a surface
Plavix Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Plavix
Clopidogrel
1900
178

Approved as Treatment by the FDA

Clopidogrel, commonly known as Plavix, is approved by the FDA for 19 uses including Acute Coronary Syndrome (ACS) and Cardiovascular Events .
Acute Coronary Syndrome (ACS)
Used to treat Acute Coronary Syndrome (ACS) in combination with Acetylsalicylic acid
Cardiovascular Events
Stroke
Atrial Fibrillation
prophylaxis of cardiovascular event
Non ST Segment Elevation Myocardial Infarction (NSTEMI)
Unstable Angina Pectoris
atherothrombotic events
Used to treat atherothrombotic events in combination with Acetylsalicylic acid
ST Segment Elevation Myocardial Infarction (STEMI)
Heart Attack
Used to treat Acute Myocardial Infarction (AMI) in combination with Acetylsalicylic acid
Angina, Unstable
Peripheral Arterial Disease
Acute Myocardial Infarction (AMI)
Used to treat Acute Myocardial Infarction (AMI) in combination with Acetylsalicylic acid
Peripheral Arterial Disease (PAD)
elegible for thrombolytic therapy
Used to treat elegible for thrombolytic therapy in combination with Acetylsalicylic acid
Heart Attack
Myocardial Infarction
Atrial Fibrillation
Acute Chest Syndrome
Used to treat Acute Coronary Syndrome (ACS) in combination with Acetylsalicylic acid

Effectiveness

How Plavix Affects PatientsClopidogrel is a medication that helps protect against heart attack and stroke. It is usually taken once a day, and the recommended dose is between 75-300mg. This drug has a long lasting effect and a wide range of safe doses.
How Plavix works in the bodyClopidogrel stops platelets from clumping together. It does this by binding to the ADP receptor on platelets, preventing them from receiving signals to form clumps. This binding is irreversible, so the platelets stay blocked from clumping together.

When to interrupt dosage

The prescribed dosage of Plavix is contingent upon the diagnosed state, including Myocardial Infarction, Cardiovascular Events and Heart Attack. The dose may vary as per the method of delivery (e.g. Tablet - Oral or Tablet, film coated - Oral) indicated in the table below.
Condition
Dosage
Administration
Atrial Fibrillation
75.0 mg, , 300.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit
Angina, Unstable
75.0 mg, , 300.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit
Heart Attack
75.0 mg, , 300.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit
prophylaxis of cardiovascular event
75.0 mg, , 300.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit
Peripheral Arterial Disease
75.0 mg, , 300.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit
Acute Chest Syndrome
75.0 mg, , 300.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit
Stroke
75.0 mg, , 300.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit
Cardiovascular Events
75.0 mg, , 300.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit
Myocardial Infarction
75.0 mg, , 300.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit
Heart Attack
75.0 mg, , 300.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit
elegible for thrombolytic therapy
75.0 mg, , 300.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit
atherothrombotic events
75.0 mg, , 300.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit

Warnings

Plavix Contraindications
Condition
Risk Level
Notes
Hemorrhage
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Clopidogrel may interact with Pulse Frequency
There are 20 known major drug interactions with Plavix.
Common Plavix Drug Interactions
Drug Name
Risk Level
Description
Abrocitinib
Major
The risk or severity of bleeding and thrombocytopenia can be increased when Clopidogrel is combined with Abrocitinib.
Almotriptan
Major
The metabolism of Almotriptan can be decreased when combined with Clopidogrel.
Amitriptyline
Major
The metabolism of Amitriptyline can be decreased when combined with Clopidogrel.
Amodiaquine
Major
The metabolism of Amodiaquine can be decreased when combined with Clopidogrel.
Anastrozole
Major
The metabolism of Anastrozole can be decreased when combined with Clopidogrel.
Plavix Toxicity & Overdose RiskClopidogrel is toxic to mice, rats, and baboons in doses of 1500-3000mg/kg. Symptoms of overdose include vomiting, difficulty breathing, gastrointestinal bleeding, and weakness. Clopidogrel binds to platelets and remains there for 11 days, meaning it cannot be removed from the bloodstream. Platelet transfusions may be used to restore the body's ability to clot if an overdose occurs.
image of a doctor in a lab doing drug, clinical research

Plavix Novel Uses: Which Conditions Have a Clinical Trial Featuring Plavix?

245 active trials are currently underway to explore the potential of Plavix in providing relief from Peripheral Arterial Disease, Acute Chest Syndrome and Heart Attack.
Condition
Clinical Trials
Trial Phases
Atrial Fibrillation
94 Actively Recruiting
Not Applicable, Phase 2, Phase 4, Phase 1, Phase 3, Early Phase 1
Angina, Unstable
2 Actively Recruiting
Not Applicable
Heart Attack
5 Actively Recruiting
Phase 2, Not Applicable, Phase 3, Phase 1
Myocardial Infarction
2 Actively Recruiting
Not Applicable, Phase 3
elegible for thrombolytic therapy
0 Actively Recruiting
Cardiovascular Events
4 Actively Recruiting
Not Applicable
Acute Chest Syndrome
2 Actively Recruiting
Not Applicable, Phase 2
atherothrombotic events
0 Actively Recruiting
Stroke
6 Actively Recruiting
Not Applicable, Phase 1
prophylaxis of cardiovascular event
0 Actively Recruiting
Peripheral Arterial Disease
36 Actively Recruiting
Not Applicable, Phase 3, Phase 1, Early Phase 1, Phase 2, Phase 4
Heart Attack
4 Actively Recruiting
Not Applicable, Phase 3

Plavix Reviews: What are patients saying about Plavix?

5Patient Review
2/17/2016
Plavix for Prevention for a Blood Clot going to the Brain
I took this medication for 14 months before I started bleeding from my large intestine. It was a close call, but I required 3 pints of blood and 2 saline solutions to get back to normal. This drug is very dangerous and it nearly killed me.
5Patient Review
1/3/2017
Plavix for Prevention for a Blood Clot going to the Brain
I began this treatment in December 2015 and have since then lost eyebrows and body hair, as well as experiencing thinning hair that doesn't grow back after waxing.
5Patient Review
3/2/2020
Plavix for Treatment to Prevent a Blood Clot in a Vascular Stent
I unfortunately had a very negative reaction to Plavix and developed drug-induced Lupus. I constantly feel flu-like, with chills, fatigue, and general malaise.
5Patient Review
12/15/2020
Plavix for Treatment to Prevent a Heart Attack
I don't know what color this is, but it really helped me.
5Patient Review
7/5/2017
Plavix for Prevention for a Blood Clot going to the Brain
I felt really fuzzy and confused after taking this medication, and it didn't feel right.
5Patient Review
12/9/2015
Plavix for Treatment to Prevent a Blood Clot in a Vascular Stent
5Patient Review
5/19/2016
Plavix for Prevention of Blood Clots in the Brain
I've been taking Plavix for ten years and it's really helped me.
4.7Patient Review
8/11/2016
Plavix for Treatment to Prevent a Blood Clot in a Vascular Stent
I would like to know if anyone has experienced severe heartburn and constipation while taking this medicine. I was on it for a year in 2009 after having a heart attack and 4 stents, but don't remember having any problems. Now the doctor has put me on it because I had a TIA, but I'm experiencing heartburn and constipation.
4.3Patient Review
5/21/2016
Plavix for Prevention for a Blood Clot going to the Brain
This drug has been keeping me alive after three strokes. I have micro vascular disease, and this medication is essential for my survival.
4Patient Review
4/19/2016
Plavix for Blood Clot Prevention Following Percutaneous Coronary Intervention
This drug unfortunately came with some pretty unpleasant side effects for me, including numbness in my face and a burning feeling in my tongue. The ringing in my ears was also incredibly loud and intrusive.
3.7Patient Review
7/1/2016
Plavix for Treatment to Prevent a Heart Attack
I bruise easily and have developed red spots on my arms.
3Patient Review
3/20/2020
Plavix for Blood Clot Prevention Following Percutaneous Coronary Intervention
I agree with the comment made by "Whats this face". Plavix is a strong blood thinner which, if used for prolonged periods of time, can lead to bleeding in the body. If I were to use it, I would take only 1/2 a tablet each day.
2.7Patient Review
5/23/2015
Plavix for Treatment to Prevent a Blood Clot in a Vascular Stent
1Patient Review
2/11/2019
Plavix for Treatment to Prevent Peripheral Artery Thromboembolism
I've been on Plavix for twenty years now, and it's prevented any further strokes. The only side effects I've experienced are the occasional nosebleed or bruise.
1Patient Review
8/23/2019
Plavix for Blood Clot Prevention Following Percutaneous Coronary Intervention
Unfortunately, this medication caused a lot of irritation in my bladder and groin area. If I kept taking it, I started to experience stinging and soreness in those areas.
1Patient Review
10/7/2015
Plavix for Prevention for a Blood Clot going to the Brain
1Patient Review
12/11/2016
Plavix for Blood Clot Prevention Following Percutaneous Coronary Intervention
The only downside I experienced with this drug was increased bruising. Other than that, it was great!
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about plavix

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are Plavix side effects?

"Bleeding that takes a long time to stop, nosebleeds, more frequent bruising, fever, muscle pain, confusion, skin rash, or itching may be signs of a problem."

Answered by AI

Is Plavix a blood thinner?

"Plavix, also known as clopidogrel, is a blood thinner that reduces the risk of blood clots. It was first approved by the FDA in 1997 and is prescribed to people who have a higher risk of cardiovascular problems, such as heart attacks or strokes."

Answered by AI

Is Plavix the same as aspirin?

"Aspirin and Plavix are two different types of drugs. Plavix is a blood thinner, while aspirin is an anti-inflammatory medication. Aspirin can also be used to reduce fever, and to treat pain and inflammation throughout the body."

Answered by AI

Is Plavix a blood thinner or antiplatelet?

"Clopidogrel is a medication that prevents your platelets from clumping together. By doing this, it lowers the risk of heart attack since most heart attacks are caused by a clot forming in the vessels supplying your heart."

Answered by AI

Is Plavix a strong blood thinner?

"Plavix, also known as clopidogrel, is a blood thinner that was first approved by the FDA in 1997. It is prescribed to people who have a higher risk of cardiovascular problems, such as heart attacks or strokes, in order to reduce the risk of blood clots."

Answered by AI

What is the drug Plavix used for?

"Clopidogrel is used to prevent heart attacks, strokes, and blood circulation disease in people who have heart disease, a recent heart attack, or a recent stroke."

Answered by AI

Clinical Trials for Plavix

Image of Inova Alexandria Hospital in Alexandria, United States.

Heparin Dosing for Blood Clots and Heart Conditions

18+
All Sexes
Alexandria, VA
The goal of this clinical trial study is to test whether a mathematical calculation, using the patient's gender, weight and kidney function, can better predict a patient's heparin goal dose than a flat number of units per patient weight can. Participants will have the first dose of heparin infusion calculated, after which if adjustments are needed, the Hospital's prebuilt table for results driven dosing for this purpose is used. The researchers will compare the time it takes for the participants to get to the desired goal using the patient's information for calculation versus patients in the past who received the medication using the flat rate. The hypothesis is that the patients with enhanced personal data, gender, weight and kidney function, included for the initial dose, will get to their goal lab value sooner and with less chance of delay or overshooting the goal. A quicker time to goal lab value is beneficial to patients in many ways, including earlier treatment of the clot or coronary issue that the patient is experiencing.
Phase 4
Waitlist Available
Inova Alexandria Hospital
Image of University of Nebraska at Omaha Health Science Collaborative in Omaha, United States.

Pulse Arrival Time for Peripheral Artery Disease

18+
All Sexes
Omaha, NE
1\) The purpose of this study is to assess segmental pulse arrival time (PAT) as an alternative biomarker to detect lower-extremity peripheral artery disease (PAD). The secondary purpose will be to investigate the impacts of age on segmental PAT. The subject population will include any adults 19 years of age or older with or without PAD. Exclusion criteria include having an aortic aneurysm with or without previous intervention, previous revascularization surgeries of the arteries in the legs/aorta, walking impairments independent of PAD, gangrene or ulcers of the toes/feet, and currently pregnant or breastfeeding. 3) All aims of the present study will be completed with a single laboratory visit. Descriptive measurements will include height, weight, age, sex, body fat percentage, and self-reported medication and health history. Subjects will lie in the supine position for 20-min. After rest, either the ankle-brachial index (ABI) or PAT will be assessed. After 10-min of further rest, the other measurement will be performed. ABIs will be assessed according to current guidelines: blood pressures will be assessed in the dorsal pedis and tibialis posterior arteries of both legs and the brachial arteries of both arms using a blood pressure cuff and Doppler ultrasound. PAT will be simultaneously assessed in both arms and legs using an investigational device with a 3-lead electrocardiogram sensor and four photoplethysmography (PPG) sensors. A PPG sensor will be applied to both middle fingers and both big toes. Signals will be collected for 15-min. Thermal images of the fingers and toes will be assessed before and after using the investigational device. After assessment of ABI and PAT, subjects will participate in a 6-min walking test (6MWT) to objectively establish walking capacity. The 6MWT will be performed in accordance with current guidelines. Cones will be separated by 30 meters on a straight flat walkway. Subjects will be instructed to walk back and forth between the cones as fast as they can for 6-min. Subjects will be allowed to rest during the test, if necessary, but the stopwatch will continue to run. Segmental PATs will be compared with ABI and 6-min walking time to determine if segmental PATs can predict lower-extremity PAD (ABI) and the associated walking impairment (6MWT). This study is expected to last \~2hrs. 4) There will be no follow-up.
Waitlist Available
Has No Placebo
University of Nebraska at Omaha Health Science Collaborative
Have you considered Plavix clinical trials? We made a collection of clinical trials featuring Plavix, we think they might fit your search criteria.Go to Trials
Image of Mission Cardiovascular Research Institute in Fremont, United States.

REGN7508 + REGN9933 for Atrial Fibrillation

18+
All Sexes
Fremont, CA
This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillation. The aim of the study is to see how well REGN7508 and REGN9933 work in patients that get medicine for their atrial fibrillation. The bleeding effects of REGN7508 and REGN9933 will be compared to another medicine (apixaban), which is available on the market to treat and prevent formation of blood clots. The study is looking at several other research questions, including: * What side effects may happen from taking REGN7508 or REGN9933 * How well do the study drugs reduce the risk of having a stroke * How much of REGN7508 or REGN9933 is in the blood at different times * Whether the body makes antibodies against REGN7508 or REGN9933 (which could make the drugs less effective or could lead to side effects)
Phase 2
Recruiting
Mission Cardiovascular Research Institute (+4 Sites)Clinical Trial ManagementRegeneron Pharmaceuticals
Have you considered Plavix clinical trials? We made a collection of clinical trials featuring Plavix, we think they might fit your search criteria.Go to Trials
Image of The Cleveland Clinic in Cleveland, United States.

Metabolic Surgery for Atrial Fibrillation

18 - 80
All Sexes
Cleveland, OH
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is estimated that between 3 and 6 million Americans are currently living with AF, while 12 million people in the United States will have AF in 2030. Obesity and its comorbidities such as type 2 diabetes (T2DM), hypertension, and obstructive sleep apnea (OSA) are major risk factors for development and progression of AF. Metabolic and Bariatric Surgery (MBS) is the most effective currently available treatment for obesity. Patients typically lose 20 to 35 percent of body weight after surgery which is often sustained for many years. MBS can improve all 5 major risk factors of AF including obesity, hypertension, T2DM, OSA, and systemic inflammation. The purpose of the study is to understand if MBS can affect the severity of AF and the toll AF's symptoms take on patients.
Phase 4
Waitlist Available
The Cleveland ClinicAli AminaniEthicon, Inc.
Image of The Ottawa Hospital Civic Campus in Ottawa, Canada.

Cardiac CT Angiography for Atrial Fibrillation and Flutter

18+
All Sexes
Ottawa, Canada
The goal of this randomized clinical trial is to learn whether patients with symptomatic atrial fibrillation or atrial flutter (AF) who require heart imaging to rule out a blood clot before cardioversion would benefit from cardiac computed tomography angiography (CCT) in the emergency department (ED) compared to current standard of care management. This will be a multicenter trial evaluating whether CCT-facilitated cardioversion in the ED reduces hospital admission, reduces repeat presentations to hospital and improves patient quality of life compared to the current standard of care. Participants will undergo CCT-facilitated cardioversion or be treated according to current standard of care while in the ED and complete quality of life questionnaires in the ED and follow-up at 30 days.
Waitlist Available
Has No Placebo
The Ottawa Hospital Civic CampusBenjamin Chow, MD PhD FRCPC FACC FESC FA
Image of Tampa General Hospital in Tampa, United States.

Fasting for Myocardial Infarction

18+
All Sexes
Tampa, FL
The goal of this clinical trial is to find out whether fasting is necessary before urgent inpatient cardiac catheterizations. For patients presenting with urgent heart-related pain or even mild heart attacks, researchers want to know whether eating and drinking before their procedure improves comfort without raising the risk of complications. The study will answer: * Does eating and drinking before the procedure improve patient comfort? * Does it increase the risk of adverse events like vomiting, aspiration (food or liquid entering the lungs), breathing problems, or death, etc? Participants will be randomly assigned to either: * A standard fasting group (no food for 6 hours, no clear liquids for 2 hours), or * A no-fasting group (able to eat and drink as usual). Patients will complete brief surveys before the procedure to assess comfort and satisfaction. Researchers will also review medical records weekly and 30 days later to monitor for safety outcomes.
Recruiting
Has No Placebo
Tampa General HospitalSamip Vasaiwala, MD
Have you considered Plavix clinical trials? We made a collection of clinical trials featuring Plavix, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security